What's new

Orphan designation: Fragment antibody targeting human TfR1 conjugated to phosphorodiamidate morpholino oligomer Treatment of Duchenne muscular dystrophy, 16/04/2025 Positive

Orphan designation: Fragment antibody targeting human TfR1 conjugated to phosphorodiamidate morpholino oligomer Treatment of Duchenne muscular dystrophy, 16/04/2025 Positive

Jun 10, 2025 - 07:05
 0
Orphan designation: Fragment antibody targeting human TfR1 conjugated to phosphorodiamidate morpholino oligomer Treatment of Duchenne muscular dystrophy, 16/04/2025 Positive
Orphan designation: Fragment antibody targeting human TfR1 conjugated to phosphorodiamidate morpholino oligomer Treatment of Duchenne muscular dystrophy, 16/04/2025 Positive
Read More

Tags:

Previous Article

Orphan designation: Adeno-associated viral vector serotype LK03 containing the h...

Next Article

China’s EV Moves in UK & EU Progressing

Related Posts

Orphan designation: Parahydroxybenzoic acid Treatment of primary ubiquinone deficiency, 16/04/2025 Positive

Orphan designation: Parahydroxybenzoic acid Treatment o...

Jun 10, 2025  0

PRAC recommendations on signals adopted at the 5-8 May ...

Jun 2, 2025  0

Scientific advice and protocol assistance adopted durin...

May 14, 2025  0